156 results about "Myocardial tissue" patented technology

The invention discloses a preparation method and application of yak blood peptide with anti-hypoxia and anti-fatigue functions. The method comprises the steps of raw material pretreatment, composite enzymolysis (adopting a mixture of enzyme digestion modified lumbrukinase and nattokinase), enzyme deactivation, separation and purification, ferrous chelation, Maillard reaction, concentration and drying and the like. The enzymolysis efficiency and the active peptide yield are remarkably improved through ultrasonic treatment and a composite enzymolysis technology, the stability and the anti-hypoxia capacity of peptide fragments are enhanced through ferrous chelation, and the antioxidant activity and the anti-fatigue activity are further improved through the Maillard reaction. Experiments show that the yak blood peptide prepared by the method can significantly improve the antioxidant enzyme activity, prolong the normal-pressure hypoxia survival time, prolong the swimming exhaustion time and significantly reduce the MDA content of brain tissue and myocardial tissue. The obtained product can be applied to anti-hypoxia and anti-fatigue medicines or health-care foods, and has the advantages of high process efficiency, remarkable activity, high safety and the like.

The invention discloses an application of isorhamnetin in preparation of an anti-myocardial fibrosis medicine, and belongs to the technical field of medicines. The invention proposes that the isorhamnetin can effectively reduce myocardial tissue collagen deposition for the first time, and the medical application of the isorhamnetin is expanded. The isorhamnetin is used as the anti-myocardial fibrosis medicine, can effectively relieve the increase of mRNA expression levels of alpha-SMA, COL-1, COL-3, p53, PAI-1, IL-1beta and IL-6, and has the function of retarding myocardial fibrosis. The isorhamnetin is used as the active component of the anti-myocardial fibrosis medicine, the safety is high, the side effect is small, a novel anti-myocardial fibrosis treatment strategy is provided, and the application blank of the isorhamnetin in the field is filled.

The invention relates to a breast cancer chemotherapy myocardial stress quantitative evaluation method, which comprises the following steps of: acquiring an electromechanical response signal of a myocardial tissue of a chemotherapy patient in a pulsation period, extracting an electromechanical coupling delay parameter of a local tissue, and identifying an initial region of a chemotherapy-induced myocardial stress reaction; for the identified stress starting region and the adjacent cardiac muscle tissue, acquiring the transcellular membrane response time difference, and calculating a stress conduction lag difference index for characterizing the chemotherapy-induced asymmetric stress conduction characteristic; controllable micro-load intervention is carried out on a patient, and a strain reaction curve of a stress starting area and peripheral tissues after the load is applied is monitored; based on the response lag time, the strain peak change rate and the dynamic trend of recovering to the baseline in the load response process, the stress response elastic coefficient of the myocardial tissue is obtained through inversion and is used for quantifying the stress level of the myocardial after breast cancer chemotherapy; tiny changes of myocardial functions are quantified, and a trend judgment basis is provided.

The invention provides a multi-mode ultrasonic monitoring method for degradation of a PFO degradable plugging device, and relates to the technical field of cardiovascular ultrasonic medical treatment. The multi-mode ultrasonic monitoring method for degradation of the PFO degradable occluder aims to overcome the technical defects that in the prior art, a single ultrasonic mode cannot achieve degradation progress quantification of the occluder, precise identification of residual shunt and evaluation of the integration degree of surrounding myocardial tissue at the same time. According to the method, three modalities of real-time three-dimensional transthoracic ultrasound (RT-3D TTE), ultrasonic contrast (CEUS) and shear wave elastography (SWE) are cooperatively applied, the form, hemodynamics and tissue elasticity data of the occluder are collected in stages, non-invasive, dynamic and accurate monitoring of the whole degradation process of the occluder is achieved in combination with preset quantitative indexes, and a reliable basis is provided for clinically adjusting a treatment scheme.

The invention relates to the technical field of medical image processing and three-dimensional reconstruction, and particularly discloses a reconstruction and analogue simulation method based on a cardiac image. The method comprises the following steps: firstly, preprocessing an input CT or MRI medical image, and automatically segmenting a heart multi-tissue structure by using an nnUNetv2 model, including a plurality of anatomical regions such as atrium, ventricle, myocardial tissue and blood pool; and then performing topology repair, smoothing processing and label resampling on the segmentation result to obtain a three-dimensional label body with a continuous structure and a complete boundary. And based on the optimized tag body, constructing a heart three-dimensional surface model by adopting a Marching Cubes algorithm, and generating a multi-material volume grid suitable for finite element analysis. According to an electrode position and a radio frequency parameter set by a user, a radio frequency ablation simulation model based on a Pennes biological heat conduction equation and an Arrhenius model is established, a temperature field and a tissue thermal damage range are calculated, and a simulation result is displayed in a three-dimensional mode in an overlapping mode. According to the method, the integrated process from medical image automatic segmentation to heart three-dimensional reconstruction and thermal simulation is realized, the segmentation precision, the modeling efficiency and the simulation reliability are improved, and the method can be applied to application scenes such as surgical planning, preoperative evaluation and medical teaching.

The invention relates to the technical field of model construction, in particular to a heart model construction method based on multiple physical fields and geometric multiple scales, which comprises the following steps of: performing segmentation processing and three-dimensional model reconstruction on a heart image to generate an initial heart geometric model; performing anisotropic attribute assignment on the initial heart geometric model based on a regularization algorithm to obtain a myocardial tissue structure; embedding a cell electrophysiological model into the computational grid of the myocardial tissue structure through parameter mapping to output a heart model with multi-scale geometric characteristics; an electrophysiological field equation, a mechanical field equation and a heart fluid dynamic field equation are constructed respectively, and coupling among multiple physical fields is achieved; determining whether the feature weight of the myocardial tissue structure texture needs to be increased or not; determining whether the transition function width of cell electrophysiological model parameter mapping needs to be increased or not; and determining a pressure feedback relaxation factor in the coupling iteration. The stability of heart model construction is improved.

The present application relates to the technical field of model construction, and particularly relates to a heart model construction method based on multi-physical field and geometric multi-scale, comprising: carrying out segmentation processing and three-dimensional model reconstruction on a heart image to generate an initial heart geometric model, carrying out anisotropic attribute assignment on the initial heart geometric model based on a regularization algorithm to obtain a myocardial tissue structure; embedding a cell electrophysiology model into a calculation grid of the myocardial tissue structure through parameter mapping to output a heart model with multi-scale geometric characteristics; respectively constructing an electrophysiology field equation, a mechanics field equation and a heart fluid dynamics field equation to realize coupling between the multi-physical fields; determining whether the feature weight of the myocardial tissue structure texture needs to be increased; determining whether the transition function width of the cell electrophysiology model parameter mapping needs to be increased; and determining a pressure feedback relaxation factor in the coupling iteration. The present application improves the stability of heart model construction.

The device comprises an operating handle, an excision cavity with an opening in one side and a cutter, a freely-extending operating rod is arranged on the operating handle, the excision cavity is formed in the free end of the operating rod, and a suction limiting mechanism connected with external negative pressure suction equipment is movably arranged in an inner cavity of the excision cavity. The suction limiting mechanism is opposite to the opening of the excision cavity, can suck hypertrophic cardiac muscle tissue to be excided into the excision cavity, and can be close to or far away from the opening of the excision cavity so as to limit and adjust the depth of an inner cavity of the excision cavity, the cutter is movably arranged at the opening of the excision cavity in parallel, and a linkage mechanism is further arranged on the operating handle. The linkage mechanism penetrates through the operating rod to be connected with the cutter, the cutter can be pushed to move in parallel from one end of the opening of the excision cavity to the other end of the opening of the excision cavity so as to excide hypertrophic cardiac muscle tissue entering the excision cavity, by adjusting the position of the suction limiting mechanism, a doctor can conveniently control the excision thickness or depth, and the operation precision is improved.

The invention discloses a three-dimensional heart chip device. The device comprises a pneumatic control layer, a flexible functional film layer and a microfluidic culture layer, wherein the flexible functional film layer is integrated with a stretchable microelectrode array with a snakelike structure, and the microfluidic culture layer is arranged on the flexible functional film layer; wherein the pneumatic control layer is used for driving the flexible functional film layer to generate periodic deformation and applying mechanical tensile strain to cardiac muscle tissues in the microfluidic culture layer, and meanwhile, the stretchable microelectrode array of the snake-shaped structure synchronously deforms along with the flexible functional film layer and keeps conformal electric contact with the cardiac muscle tissues, so that the mechanical tensile strain is applied to the cardiac muscle tissues in the microfluidic culture layer. The electrophysiological signals are monitored in the dynamic mechanical stretching process. The technical problem that in the prior art, stable electrophysiological monitoring cannot be carried out while dynamic mechanical stretching is applied is solved, physiologically-related mechanical stimulation can be applied to three-dimensional cardiac muscle tissue to promote maturity of the three-dimensional cardiac muscle tissue, and long-term and stable in-situ electrophysiological signal monitoring is achieved in the process; and a more accurate in-vitro model is provided for drug screening and disease research.

To provide a system and method for generating, visualizing, and displaying cardiac signal information present at different depths in cardiac tissue. [Solution] Electroanatomical mapping of cardiac tissue is created at different depths using a multi-electrode catheter that collects electrical activity from within the patient's heart. Signal analysis of the electrical activity at a first location is performed based on the electrical activity received from multiple electrodes. The depth of the electrical activity at the first location is determined according to the signal analysis. This process is repeated at more than one depth for multiple further surface locations of the cardiac tissue. Multiple electroanatomical maps of the heart are generated, and the maps show the electrical activity at different depths of the cardiac tissue.

This invention belongs to the field of biomedical engineering technology, providing a method for preparing modular bio-ink for cell spheres and its application in the field of myocardial repair therapy. First, a method for preparing stem cell spheres based on microarrays is described. By introducing a protein / polyphenol composite coating onto the cell spheres, a multifunctional armor is created, providing immune protection and immunomodulatory therapy against the host's immune system to reverse the hostile microenvironment and promote the healing process of infarcted myocardial tissue. Second, using microfluidic droplet control technology, gel microspheres loaded with bioactive substances are prepared from biocompatible biomaterials. These microspheres are then densely packed and coated to form cell sphere particle gels. These gels can be used for disease treatment via direct injection or bio-3D printing, showing promising application prospects.

The invention is entitled "Breath control during cardiac ablation." The invention discloses a method for invasive cardiac treatment, the method comprising inserting a catheter into a beating heart of a patient who is anesthetically paralyzed and intubated for ventilation via a transvascular path, and temporarily stopping ventilation of the patient after the catheter is inserted. The method comprises moving the catheter between a plurality of locations of myocardial tissue of the heart with the ventilation stopped, and ablating the myocardial tissue of the heart at the plurality of locations with the ventilation stopped.

The invention belongs to the technical field of medical instruments, and particularly relates to an artificial mitral valve suture-free automatic implantation device which comprises a catheter, one end of the catheter is fixedly connected with an opening and closing puncture mechanism, the inner wall of the catheter is fixedly connected with a pushing mechanism, a groove is formed in the outer surface of the catheter, and a filling solvent bag is installed in the groove; through the arranged opening and closing puncture mechanism, the opening and closing puncture head enters the human body with the minimum incision and then is expanded after entering the human body, the initial puncture point is extremely small, direct injury to tissues such as blood vessels and cardiac muscle can be reduced, the path of the automatically expanded needle head is more regular, important blood vessels, nerves or cardiac muscle tissues can be avoided, the accidental injury risk is reduced, and the working efficiency is improved. According to traditional implantation, a puncture channel possibly needs to be expanded in advance, an open-close type needle head is automatically expanded after entering, an additional expansion step is not needed, traction and extrusion on surrounding tissue are reduced, and the possibility of hematoma and infection after an operation is reduced.

A delivery system and method are described that include a catheter (102) and a stylet (200). The catheter (102) defines a delivery lumen (146) therethrough. The stylet (200) extends through the delivery lumen (146) of the catheter (102) and is movable relative to the catheter (102). The stylet (200) includes a tip section (220) at a distal end (212) of the stylet (200). The tip section (220) selectively transitions between a narrow state and a flared state. The tip section (220) in the flared state has a greater lateral extension than the tip section (220) in the narrow state. The tip section (220) in the narrow state is configured to project beyond a distal end (116) of the catheter (102) to pierce cardiac tissue. The tip section (220) is configured to transition from the narrow state to the flared state to anchor the stylet (200) to the cardiac tissue.

This invention provides a traditional Chinese medicine compound for treating viral myocarditis, belonging to the field of traditional Chinese medicine pharmaceutical technology. The compound consists of Forsythia suspensa, Fagopyrum dibotrys, Pseudostellaria heterophylla, Rhodiola rosea, Citrus medica, Allium macrostemon, Poria cocos, Gynostemma pentaphyllum, Salvia miltiorrhiza, Dalbergia odorifera, Cynanchum paniculatum, and Valeriana. This traditional Chinese medicine compound exhibits significant protective effects against viral myocarditis, specifically by significantly reducing damage to H9c2 cardiomyocytes caused by CVB3 virus. Its mechanism of action is closely related to downregulating the expression of inflammatory factors TNF-α and IL-6 and inhibiting the inflammatory response. Simultaneously, within the experimental concentration range, the compound shows no toxicity to cardiomyocytes, demonstrating good biocompatibility. Furthermore, this compound can significantly reduce myocardial tissue damage in a viral myocarditis model mouse by inhibiting the in vivo inflammatory response and regulating oxidative stress imbalance, providing a safe and effective new treatment option for the clinical treatment of viral myocarditis.

The invention relates to an MOTS-c targeted delivery system based on an exosome derived from astragalus membranaceus and application of the MOTS-c targeted delivery system in myocardial ischemia-reperfusion injury. The preparation method comprises the following steps: preparing an exosome AExo from radix astragali from fresh radix astragali as a raw material, modifying a cardiac troponin I targeting peptide LPFFD to the surface of the AExo by using an EDC / NHS chemical cross-linking method to obtain LPFFD-AExo, and loading a mitochondrial derived small peptide MOTS-c into the LPFFD-AExo by using an ultrasonic-assisted penetration method to obtain the LPFFD-AExo-MOTS-c. According to the invention, the accurate delivery efficiency of the damaged myocardial tissue can be improved, and efficient and accurate delivery of MOTS-c to the ischemia reperfusion damaged myocardial tissue is realized, so that the ferroptosis inhibition capability of MOTS-c is obviously enhanced, the myocardial protection effect on MI / R injury is improved, and finally efficient targeted therapy on MI / R injury is realized.

A catheter system for use with a catheter with a distal assembly supporting a plurality of electrodes adapted to sense electrical signal in heart tissue and a force sensor configured to generate first contact signals representative of a contact force acting on the distal assembly. The system includes an ablation power generator configured to energize the plurality of electrodes, an impedance circuitry configured to generate second contact signals representative of the electrodes in contact with tissue, a processor configured to receive the first and second contact signals and generate switch signals in response thereto, and a switch circuitry configured to connect in response to the switch signals solely selected electrodes in contact with tissue to the ablation power generator in forming one or more composite electrodes.

The disclosed technology relates to a catheter configured to reduce microvascular obstruction (MVO) in myocardial tissue at risk due to an acute myocardial infarction (AMI). The catheter comprises a catheter shaft that is configured to be inserted into a heart of a patient. A channel is arranged in the heart and is configured to deliver blood from a first location in the heart to a second location in the heart. A pressure sensor is configured to monitor pressure at the second location to ensure controlled delivery of blood from the first location to the second location. The catheter device is operable to reduce the amount of tissue actually comprising MVO by approximately 20% compared to untreated regions.

The invention belongs to the technical field of medicines, and particularly relates to application of indole-3-propionic acid in preparation of a medicine for treating myocardial ischemia-reperfusion injury. A stable and reliable mouse MIRI model is successfully constructed through a coronary artery ligation left anterior descending branch reperfusion method, and it is found through indole-3-propionic acid (IPA) intervention and multi-dimensional evaluation that IPA administration can significantly improve the left ventricular ejection fraction LVEF and the left ventricular short-axis shortening rate LVFS of a model mouse, reduce the left ventricular end diastolic inner diameter LVEDd and the end systolic inner diameter LVESd, and significantly improve the model mouse left ventricular ejection fraction LVEF, the left ventricular end diastolic inner diameter LVEDd and the left ventricular end diastolic inner diameter LVESd. The heart function is effectively improved; the myocardial fibrosis area can be reduced, the mRNA expression of fibrosis-promoting and pathological hypertrophy-promoting molecules in myocardial tissues can be obviously reduced, and the myocardial injury progress can be inhibited in a multi-dimensional manner. The invention provides a brand new strategy for treating myocardial ischemia reperfusion injury, has important application value and wide clinical transformation prospect, and is expected to provide a new direction for clinical treatment.

This invention relates to the field of congenital heart disease treatment technology, and discloses the application of sapropterin in the prevention and treatment of bisphenol fluorene-induced congenital heart disease in fetuses. The congenital heart disease includes cardiac structural defects, heart failure, or cardiomyocyte lesions, specifically selected from ventricular septal defects, atrial septal defects, tetralogy of Fallot, myocardial hypertrophy, decreased cardiac ejection fraction, decreased short-axis contraction rate, cardiomyocyte ferroptosis, myocardial tissue inflammatory infiltration, or myocardial collagen fibrosis. Sapropterin is used as a direct supplement to biological tetrahydropterin (BH4). Through exogenous intervention, it precisely reverses the endogenous BH4 deficiency caused by bisphenol fluorene exposure, restores the expression of GTP cyclase 1 (GCH1) and the dynamic balance of RNA m6A, and upregulates the level of YTH domain family protein 2 (YTHDF2), thereby blocking ferroptosis signal transduction, reducing oxidative stress and inflammatory response, and inhibiting the process of myocardial tissue fibrosis at the molecular level.

A catheter utilizes a distal electrode array configured for quantification of endocardial or epicardial propagation velocity, with electrodes defining approximately equilateral triangles, such that the calculated velocity can be approximated regardless of the wave front direction. The distal electrode array can also include resilient splines carrying the electrodes such that the splines can deform to ensure contact between the electrodes and the heart tissue. Additionally, the electrodes of the distal electrode array can be individually addressable. Bipolar ablation lines or boxes can also be implemented using two parallel catheters at the endocardium and at the epicardium. Certain configurations include one or more distal electrode arrays of sufficient size to span an entire ventricular tachycardia (VT) circuit. The catheter may also be configured to detect block lines by pacing from edge pacing electrodes of the distal electrode array, and / or to detect fiber orientation by pacing from several edge pacing electrodes.

This application relates to the field of finite element analysis technology, and in particular to a method and related apparatus for generating finite element meshes based on myocardial tissue pathological slices. The method includes: extracting spatial features from myocardial tissue pathological slice images to obtain intermediate layer features; inputting each image patch into a Transformer module to obtain hidden features; concatenating the hidden features with the intermediate layer features to obtain semantic segmentation results; determining a tissue category prediction mask; determining the tissue category; extracting the contour edge pixel regions of each tissue and generating a multi-category comprehensive mask image; and performing label recognition on the multi-category comprehensive mask image to generate finite element meshes with different material properties. This application enables effective and accurate analysis of key functional microstructures, eliminating the cumbersome process of manually converting histological slices into finite element geometry and meshes, which is highly dependent on traditional methods, thus laying a solid foundation for computational modeling simulation and microstructure analysis.

The invention discloses application of functional protein STEAP3 in preparation of drugs for preventing, diagnosing and / or treating heart failure and medical inspection products, and belongs to the technical field of medicines. The invention discloses application of targeted regulation of STEAP3 in preparation of drugs for prevention, diagnosis and / or treatment of heart failure and medical inspection products. Experiments prove that targeted regulation of the protein can significantly improve the activity of cardiac muscle cells and enhance the ability of the protein to resist stress injury, and the protein also has the following five significant activities in DOX-induced heart failure model mouse in-vivo experiments: 1) improving cardiac dysfunction; the traditional Chinese medicine composition has the effects of clearing away heat and toxic materials, reversing myocardial tissue fibrosis, improving myocardial tissue sarcoma disorder, relieving myocardial cell apoptosis and reducing myocardial cell mitochondria damage.

The invention belongs to the technical field of biological medicine and nano-drugs, and discloses a liposome nano-particle for treating cardiomyopathy and a preparation method and application thereof, the liposome nano-particle is composed of phospholipid, cholesterol, functionalized lipid and a drug for treating cardiomyopathy according to a specific mass ratio, wherein the mass ratio of the phospholipid to the cholesterol to the functionalized lipid is (60-80): (10-20): (5-20), and the mass ratio of the medicine to the total lipid is (1: 10)-(1: 50). The preparation method comprises the steps of lipid film formation, vacuum drying, buffer solution hydration, extrusion granulation, purification sterilization and the like, and targeting molecules can be further connected. By optimizing a lipid prescription and a process, nanoparticles with uniform particle size, high encapsulation efficiency and good stability are successfully prepared, myocardial targeted delivery and slow release of drugs can be realized, enrichment of the drugs in myocardial tissues can be remarkably improved by the preparation, the preparation shows a treatment effect superior to that of non-targeted preparations and free drugs in a cardiomyopathy model, and the preparation has a wide application prospect. And a new strategy is provided for accurate and efficient treatment of cardiomyopathy.

To provide a system and method for generating, visualizing, and displaying cardiac signal information present at different depths in cardiac tissue. [Solution] This disclosure relates to electroanatomical mapping of cardiac tissue at different depths using a multi-electrode catheter. The multi-electrode catheter in the patient's heart has a first plurality of electrodes on a first side and a second plurality of electrodes on a second side, with the first side facing close to cardiac tissue at a first position and the second side facing away from cardiac tissue. Electrical activity is received from at least one electrode on the first side and at least one electrode on the second side, and signal analysis is performed thereon, at least partially based on the distance between the electrodes on the different sides of the multi-electrode catheter. This process is repeated for further locations of cardiac tissue in the heart, and an electroanatomical map of the heart showing electrical activity or scar tissue is generated based on the signal analysis.

The present application relates to the technical field of image fusion, and discloses a heart failure follow-up data visualization processing method based on multi-modal image fusion, comprising the following steps: constructing a left ventricular fiber direction field and extracting fusion scalar data along the fiber path, establishing an isochronous scalar complex quantification model for describing the change pattern of activation time in the fiber direction, and taking the model as a continuous control variable to participate in subsequent filtering, reconstruction and visualization coding processes. The method completes the structured arrangement of the scalar data along the integral path of the fiber, so that the fusion data is more consistent with the propagation law of the myocardial tissue when outputting the polar coordinate graph and the three-dimensional ventricular coloring graph, and can visually inhibit and prompt the local non-continuous fluctuation.

This application relates to a coronary sinus and left atrium shunt system, belonging to the field of medical device technology. The system described in this application, by setting up a puncture component and a shunt component including a cutter, allows for the cutting of a portion of myocardial tissue between the coronary sinus and the left atrium, forming a shunt orifice. This establishes a shunt channel between the coronary sinus and the left atrium, effectively avoiding the embolism risk associated with atrial septal shunts and improving coronary artery blood perfusion, potentially benefiting myocardial recovery.

The invention discloses application of rehmannia D in preparation of a product for preventing and / or treating myocardial injury, and belongs to the technical field of medicines. The myocardial injury comprises myocardial injury induced by doxorubicin (DOX), and experiments prove that the rehmannia D can obviously improve the heart function decline caused by the DOX; the myocardial cell atrophy induced by DOX can be obviously inhibited; the level of myocardial tissue fibrosis induced by DOX can be obviously inhibited; the DOX-induced myocardial tissue oxidative stress level can be obviously inhibited; in addition, DOX-induced myocardial tissue DNA damage (gamma-H2AX is taken as a marker) can be obviously inhibited. The invention proves that the rehmannia glycoside D can be used as a novel treatment means to be applied to treatment of adriamycin-induced myocardial injury, and the risk of treatment interruption or heart failure due to cardiotoxicity caused by chemotherapy of a patient can be possibly reduced, so that the disease burden of the patient and the pressure of a medical system are relieved.

The invention discloses a class of fluorobenzoyl anthracycline derivatives, and preparation method for preparing and applications of the same. The fluorobenzoyl anthracycline derivatives have chemical formula ofwhere R1 is selected from the group consisting of —CH3, —CH2OH and —O—CH3 groups; R2 is selected from the group consisting of —H, —OH and —O—CH3 groups; and R3 is a trifluoromethyl-substituted benzoyl group or a trifluoromethylphenyl-substituted benzoyl group. The preparation method involves the derivatization of fluorobenzoyl groups on the amino group of anthracycline derivatives. These derivatives act as ablation media for chemical ablation of heterogeneous myocardial tissues, achieving effective myocardial damage with targeted localization and controllable damage characteristics.

The invention discloses application of a membrane-bound O-acyltransferase structural domain 7 (Mboat7) in preparation of a medicine for treating myocardial infarction, and belongs to the technical field of biology. A research result shows that in a mouse myocardial infarction model, compared with a control group mouse, the death rate of a myocardial cell specific Mboat7 gene overexpressed mouse is reduced, the infarction area is remarkably reduced, and the cardiac function is remarkably improved; the overexpressed Mboat7 gene can relieve mitochondrial damage of myocardial cells under the hypoxia condition and improve the mitochondrial oxidative phosphorylation function. Particularly, overexpression of the Mboat7 gene can improve damage of mitochondria in myocardial tissues of mice suffering from myocardial infarction. The results show that Mboat7 gene overexpression can relieve myocardial damage after myocardial infarction so as to delay the progress of heart failure, and Mboat7 or an expression promoter thereof can be used for preparing the medicine for preventing, relieving and / or treating myocardial infarction.